Abstract
Anorexia Nervosa (AN) is a complex disease that impairs the metabolic, mental and physiological health of affected individuals in a severe and sometimes lethal way. Many of the common symptoms in AN patients, such as reduced food intake, anxiety, impaired gut motility or overexercising are connected to both the orexigenic gut hormone ghrelin and the dopaminergic system. Targeting the ghrelin receptor (GhrR) to treat AN seems a promising possibility in current research. However, GhrR signaling is highly complex. First, the GhrR can activate four known intracellular pathways Gαq, Gαi/o, Gα12/13 and the recruitment of β-arrestin. Biased signaling provides the possibility to activate or inhibit only one or a subset of the intracellular pathways of a pleiotropic receptor. This allows specific targeting of physiological functions without adverse effects. Currently little is known on how biased signaling could specifically modulate GhrR effects. Second, GhrR signaling has been shown to be interconnected with the dopaminergic system, particularly in the context of AN symptoms. This review highlights that a biased agonist for the GhrR may be a promising target for the treatment of AN, however extensive and systematic translational studies are still needed and the connection to the dopaminergic system has to be taken into account.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 734547 |
Tidsskrift | Frontiers in Endocrinology |
Vol/bind | 12 |
Antal sider | 13 |
ISSN | 1664-2392 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:The Lundbeck Foundation Ascending Investigators grant (R344-2020-810)– To study “Biased ligands for the ghrelin receptor as treatment for Anorexia Nervosa” and The Novo Nordisk Foundation - Project grants in Endocrinology and Metabolism – Nordic Region (0057417).
Publisher Copyright:
© Copyright © 2021 Khelifa, Skov and Holst.